

2025  
(Pharmacy)



# GNIPST BULLETIN

Volume-3, Issue- 4

GURU NANAK INSTITUTE OF PHARMACEUTICAL  
SCIENCE AND TECHNOLOGY


157/F, Nilgunj Road, Kolkata- 700114, West Bengal, India



# Table of Contents

- 01** Message from Director and Principal
- 02** Recent Researches
- 03** New Drug Approvals
- 04** Clinical Trial News
- 05** Disease Outbreak News
- 06** Campus News
- 07** Special Page and Game time





## MESSAGE FROM HONORABLE DIRECTOR

As the Director of Guru Nanak Institute of Pharmaceutical Science and Technology, I extend my warmest greetings and best wishes to our students, faculty, staff, alumni, and well-wishers on the joyous occasion of Diwali—the Festival of Lights.

Diwali symbolizes the triumph of light over darkness, knowledge over ignorance, and hope over despair. It reminds us that with unity, wisdom, and compassion, we can illuminate not only our surroundings but also the lives of those around us.

At GNIPST, we believe that education, like light, dispels ignorance and paves the way for progress and enlightenment. Our collective pursuit of academic excellence, innovation, and ethical responsibility continues to brighten the path toward a stronger, more enlightened future in Pharmaceutical Sciences.

May this Diwali inspire us all to spread positivity, harmony, and knowledge, while embracing new beginnings with renewed energy and purpose.

Wishing everyone a Happy, Safe, and Prosperous Diwali!

May the festival bring peace, joy, and success to you and your loved ones.

*Prof. (Dr.) Abhijit Sengupta*



## MESSAGE FROM HONORABLE PRINCIPAL

I extend my warm greetings and best wishes to our students, faculty, staff, alumni, and valued partners on the joyous occasion of Diwali—the Festival of Lights. This festival symbolizes the victory of light over darkness, knowledge over ignorance, and good over evil. It reminds us of the power of wisdom, compassion, and unity in illuminating not only our lives but also the lives of those around us.

At Guru Nanak Institute of Pharmaceutical Science and Technology (GNIPST), we believe that education is the truest form of light—dispelling ignorance, inspiring discovery, and guiding us toward excellence. Since our inception in 2005, GNIPST has grown into a distinguished centre of pharmaceutical education, recognized by the Pharmacy Council of India (PCI) and honoured as the first pharmacy institution in the region to achieve both NAAC and NBA accreditations. Our recent accomplishment of securing the 85th rank in NIRF 2025 stands as a proud reflection of our collective dedication, perseverance, and pursuit of quality.

As we celebrate this radiant festival, let us rekindle our inner light—of knowledge, integrity, and compassion—and continue our journey toward innovation, academic excellence, and social responsibility. Together, let us pledge to spread the light of learning and humanity in every sphere of life. Wishing everyone a Happy, Safe, and Prosperous Diwali!

May this festival bring joy, peace, and success to you and your loved ones.

*Prof. (Dr.) Lopamudra Datta*



## RECENT RESEARCHES



**Uncontrolled high blood pressure puts over a billion people at risk**

**MORE INFO**

[www.who.int/](http://www.who.int/)

The World Health Organization (WHO) today released its second Global hypertension report, showing that 1.4 billion people lived with hypertension in 2024, yet just over one in five have it under control either through medication or addressing modifiable health risks. The new report – released at an event co-hosted by WHO, Bloomberg Philanthropies, and Resolve to Save Lives during the 80th United Nations General Assembly – also reveals that only 28% of low-income countries report that all WHO-recommended hypertension medicines are generally available in pharmacies or primary care facilities. Hypertension is a leading cause of heart attack, stroke, chronic kidney disease, and dementia. It is both preventable and treatable – but without urgent action, millions of people will continue to die prematurely, and countries will face mounting economic losses. From 2011 to 2025, cardiovascular diseases – including hypertension – are projected to cost low- and middle-income countries approximately US\$ 3.7 trillion, equivalent to around 2% of their combined GDP.

**WHO Traditional Medicine Global Library to launch in 2025**

**MORE INFO**

[www.who.int/](http://www.who.int/)

The World Health Organization (WHO) is preparing to launch the world's most comprehensive digital knowledge repository for traditional, complementary and integrative medicine. The Traditional Medicine Global Library (TMGL) will be released in December 2025 at the upcoming WHO Global Summit on Traditional Medicine in New Delhi, India.

**Recommendations announced for influenza vaccine composition for the 2026 southern hemisphere influenza season**

**MORE INFO**

[www.who.int/](http://www.who.int/)

The World Health Organization (WHO) today announced its recommendations for the viral composition of influenza vaccines for use in the 2026 influenza season in the southern hemisphere. The announcement was made at an Information Meeting after a 4-day Consultation on the Composition of Influenza Virus Vaccines. Given the constantly evolving nature of influenza viruses, regular updates to vaccine composition are essential to ensure their effectiveness and to protect public health worldwide. WHO convenes these consultations twice annually – once for the southern hemisphere and once for the northern hemisphere, bringing together an advisory group of experts from WHO Collaborating Centres and Essential Regulatory Laboratories. The group reviews surveillance and other data provided by the WHO Global Influenza Surveillance and Response System (GISRS) and collaborators to inform its recommendations.



FDA



# NEW DRUG APPROVALS

September, 2025

Inlexzo (gemcitabine) intravesical system – formerly TAR-200

- Date of Approval: September 9, 2025
- Company: Johnson & Johnson
- Treatment for: Bladder Cancer



Bosaya (denosumab-kyqq) Injection

- Date of Approval: September 16, 2025
- Company: Biocon Biologics Ltd.
- Treatment for: Osteoporosis

Subvenite (lamotrigine) Oral Suspension

- Date of Approval: September 16, 2025
- Company: OWP Pharmaceuticals, Inc.
- Treatment for: Epilepsy

Rhapsido (remibrutinib) Tablets

- Date of Approval: September 30, 2025
- Company: Novartis
- Treatment for: Urticaria

Enbumyst (bumetanide) Nasal Spray

- Date of Approval: September 15, 2025
- Company: Corstasis Therapeutics Inc.

Aukreso (denosumab-kyqq) Injection

- Date of Approval: September 16, 2025
- Company: Biocon Biologics Ltd.
- Treatment for: Osteolytic Bone Lesions of Multiple Myeloma

Inluriyo (imlunestrant) Tablets

- Date of Approval: September 25, 2025
- Company: Eli Lilly and Company
- Treatment for: Breast Cancer



<https://www.drugs.com/newdrugs.html>





# CLINICAL TRIAL NEWS


**01.**

## Merck's Investigational Oral PCSK9 Inhibitor Enlicitide Decanoate Met All Primary and Key Secondary Endpoints in Adults with Hypercholesterolemia in Pivotal CORALreef Lipids Study

September 2, 2025 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 3 CORALreef Lipids trial evaluating the safety and efficacy of enlicitide decanoate, an investigational, once-daily oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor being evaluated for the treatment of adults with hypercholesterolemia on a moderate or high intensity statin (or with documented statin intolerance).

**02.**

## Lilly's Olomorasib Receives U.S. FDA's Breakthrough Therapy Designation for the Treatment of Certain Newly Diagnosed Metastatic KRAS G12C-Mutant Lung Cancers

INDIANAPOLIS, Sept. 4, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to olomorasib, in combination with anti-PD-1 therapy KEYTRUDA (pembrolizumab), for the first-line treatment of patients with unresectable advanced or metastatic non-small cell lung cancer (NSCLC) with a KRAS G12C mutation and PD-L1 expression  $\geq 50\%$ , as determined by FDA approved tests.

**03.**

## Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025 E2086 Showed Potential to Improve Wakefulness in People Living with Narcolepsy Type 1

September 8, 2025 -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the results from a Phase 1b clinical trial (NCT06462404) of its in-house developed novel selective orexin 2 receptor agonist E2086 have been presented at the World Sleep 2025 congress, held in Singapore from September 5 to 10.

**04.**

## Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies

TARRYTOWN, N.Y., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced results evaluating its first-in-class investigational allergen-blocking antibodies in allergen-challenge Phase 3 trials in adults with moderate-to-severe cat or birch allergies. Both trials met their respective primary and key secondary endpoints. Data from the Phase 3 trials will be presented at an upcoming medical conference and will inform confirmatory Phase 3 trials.

**05.**

## Lilly's oral GLP-1, Orforglipron, Demonstrated Meaningful Weight Loss and Cardiometabolic Improvements in Complete ATTAIN-1 Results Published in The New England Journal of Medicine

INDIANAPOLIS, Sept. 16, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from the Phase 3 ATTAIN-1 trial, evaluating the safety and efficacy of orforglipron, an investigational oral glucagon-like peptide-1 (GLP-1) receptor agonist, in adults with obesity, or overweight with a weight-related medical problem and without diabetes. At 72 weeks, all three doses (6 mg, 12 mg and 36 mg) of orforglipron met the primary endpoint of superior body weight reduction compared to placebo. In addition, all three doses delivered clinically meaningful results compared to placebo across the key secondary endpoints of body weight reduction ( $\geq 10\%$ ,  $\geq 15\%$  and  $\geq 20\%$ ), and waist circumference reduction.<sup>i</sup> Results from the trial were presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2025 and simultaneously published in The New England Journal of Medicine.

**06.**

## Johnson & Johnson's Investigational Seltorexant Shows Numerically Higher Response in Patients with Depression with Insomnia Symptoms, with Fewer Side Effects Compared to Quetiapine XR

TITUSVILLE, NJ. (September 22, 2025) – Johnson & Johnson announced results from the Phase 3 MDD3005 26-week clinical trial evaluating the efficacy and safety of seltorexant compared to quetiapine extended release (XR) as an adjunctive treatment in adult and elderly patients with major depressive disorder (MDD) with insomnia symptoms. The findings were presented at this year's annual U.S. Psychiatric and Mental Health Congress (Psych Congress), held from September 17-21 in San Diego, California.


**07.**

## Umoja Biopharma Announces that UB-VV111 Receives FDA Fast Track Designation for Relapsed/Refractory B-Cell Malignancies

SEATTLE, WA, September 30, 2025 — Umoja Biopharma, the clinical-stage leader of in vivo cell therapies that aim to realize the full reach and promise of CAR T cells, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to UB-VV111 for the treatment of relapsed/refractory Large B-cell Lymphoma following two or more lines of prior therapy and relapsed/refractory Chronic Lymphocytic Leukemia following two or more lines of prior therapy.

**MORE INFORMATION**

[https://www.drugs.com/clinical\\_trials\\_archive/january-2025.html](https://www.drugs.com/clinical_trials_archive/january-2025.html)



# DISEASE OUTBREAK NEWS (DONS)



September, 2025

## Nipah virus infection - Bangladesh

18 September 2025

### Situation at a glance

Between 1 January and 29 August 2025, the International Health Regulations National Focal Point (IHR NFP) for Bangladesh notified WHO of four confirmed fatal Nipah virus (NiV) infection cases, temporally unrelated, reported from four different districts across three separated geographical divisions (Barisal, Dhaka, and Rajshahi) in Bangladesh. NiV infection is a zoonotic disease transmitted to humans through infected animals (such as bats or pigs), or food contaminated with saliva, urine, and excreta of infected animals. It can also be transmitted directly from person to person through close contact with an infected person. Fruit bats or flying foxes (*Pteropus* species) are the natural hosts for the virus. Human NiV infection is an epidemic-prone disease that can cause severe disease in humans and animals, with a high mortality rate, and outbreaks primarily occurring in South and South-East Asia. Since the first recognized outbreak in Bangladesh in 2001, human infections have been detected almost every year. To date, Bangladesh has documented 347 NiV cases through its Nipah surveillance system established to detect and respond to outbreaks promptly, with a case fatality rate of 71.7%. There are currently no specific drugs or vaccines for NiV infection; intensive supportive care is recommended to treat severe respiratory and neurologic complications. Public health efforts should focus on raising awareness of risk factors, promoting preventive measures to reduce exposure to the virus, and on early case detection supported by adequate intensive supportive care. The Ministry of Health and Family Welfare in Bangladesh has implemented several public health measures with support from WHO. WHO assesses the overall public health risk posed by NiV at the national and regional levels to be moderate; the risk of international disease spread is considered low. 4738 deaths were reported globally, from 31 countries, with six of the 31 countries



MORE INFO



<https://www.who.int/emergencies/disease-outbreak-news/item/2025-DON573>

## Ebola virus disease - Democratic Republic of the Congo

5th September, 2025

### Situation at a glance

On 1 September 2025, WHO received an alert from the Ministry of Health of the Democratic Republic of the Congo (DRC) regarding suspected cases of Ebola virus disease (EVD) in the Bulape Health Zone, Kasai Province, DRC. The first known index case was a pregnant woman who presented at Bulape General Reference Hospital on 20 August 2025 with symptoms of high fever, bloody diarrhoea, haemorrhage and extreme weakness. She died on 25 August from multiple organ failure. On 4 September 2025, following confirmatory laboratory testing, the Ministry of Health declared an outbreak of EVD. Ebola virus disease is a serious, often fatal illness in humans. The virus is transmitted to humans through close contact with the blood or secretions of infected wildlife and then spreads through human-to-human transmission. As of 4 September 2025, 28 suspected cases, including 15 deaths (case fatality ratio (CFR): 54%), have been reported from three areas of the Bulape health zone (Bulape, Bulape Com and Dikolo) and Mweka health zone. Among the deaths, four are health-care workers.




MORE INFO

<https://www.who.int/emergencies/disease-outbreak-news/item/2025-DON566>



# GNIPST GAME TIME



## Word Search Hints- laboratory equipment's

W	E	T	R	B	O	F	S	P	Q
O	C	S	N	U	H	U	K	V	M
P	O	Q	H	R	O	N	F	Q	L
Q	N	S	F	E	P	N	R	H	S
P	I	P	E	T	T	E	U	O	D
E	C	A	S	T	D	L	T	U	G
S	A	T	B	E	A	K	E	R	V
T	L	U	R	U	G	Y	S	I	B
L	F	L	T	T	H	P	T	U	T
E	L	A	U	R	J	F	T	Z	Y
Y	A	K	G	U	I	H	U	B	J
S	S	D	V	H	N	N	B	X	K
G	K	Q	F	A	S	E	E	N	L

Stay tuned for to the next edition for a shout out to fastest correct answers!

**Submit your answer**



or

**CLICK  
HERE**

## Celebrating the Achievers!

Volume -3, Issue -3



Rupam Dalal

B.Pharm, 5th Semester

Guru Nanak Institute of Pharmaceutical Science and Technology



# THE FESTIVAL OF LIGHTS AND POWER



Diwali, also known as Deepavali, and Kali Puja are two of India's most vibrant and spiritually significant festivals, often celebrated together with great devotion and enthusiasm. While Diwali symbolizes the victory of light over darkness, good over evil, and hope over despair, Kali Puja honors the fierce and protective form of Goddess Kali, who destroys evil forces and safeguards her devotees. During this time, homes, temples, and streets are illuminated with diyas and lights, creating an atmosphere filled with faith, energy, and divine grace.

- It celebrates the return of Lord Rama to Ayodhya after his victory over Ravana, symbolizing the triumph of righteousness.
- People worship Goddess Lakshmi, the goddess of wealth and prosperity, to invite abundance and happiness into their homes.
- The festival fosters unity, peace, and cultural harmony across all regions.
- Kali Puja, celebrated mainly in eastern India, honors Goddess Kali, representing strength, protection, and the destruction of evil.
- Homes are cleaned, beautifully decorated, and filled with light, while families share sweets, gifts, and festive joy.
- 

Together, Diwali and Kali Puja inspire everyone to spread light, courage, and positivity while removing ignorance and negativity from life.



# CAMPUS NEWS



**1. National Seminar:** GNIPST organized a National Seminar on “Schedule M: The Regulatory Compliance in Pharmaceutical Manufacturing” on 18th September 2025 at the GNIPST Auditorium.



**2. Educational Tour:** GNIPST organized an Educational Tour at Bose Institute for our B. Pharm 1st year students.

The visit provided valuable insights into cutting-edge research and inspired young minds to explore the world of science and innovation.



**3. National Seminar:** GNIPST successfully organized a One-Day Seminar on “Role of Host Immune Response in Infectious Diseases” at the GNIPST Auditorium.



**4. World Pharmacist Day celebration:** On the occasion of World Pharmacist Day 2025, GNIPST organized a rally to spread awareness about the pivotal role of pharmacists in healthcare. Students, faculty, and staff enthusiastically participated, showcasing their dedication towards the profession and society.



**5. Rangoli Exhibition:** The Literary and Painting Club of GNIPST organized a Rangoli Exhibition on the occasion of Pre-Diwali Celebration!

The event was filled with colors, creativity, and festive spirit as students showcased their artistic talents and celebrated the festival of lights with joy and enthusiasm.



# Editorial Board

## Editor- in- Chief

*Prof. (Dr.) Abhijit Sengupta*

## Managing Editors

Prof. (Dr.) Lopamura Datta

## Associate Editors

Mr. Tushar Adhikari

Ms. Manjarima Ganguli

## Editorial Board Members

Mrs. Indrani Banerjee Chakraborty

Mr. Arpan Dutta

Ms. Ananya Chandra

Ms. Parnasree Chakraborty

Ms. Lopamudra Saha

Mr. Sarthak Saha



## COURSES OFFERED

### PHARMACY UG COURSES

- Bachelor of Pharmacy (B.Pharm)

### PHARMACY DIPLOMA COURSES

- Diploma in Pharmacy (D.Pharm)

### PHARMACY PG COURSES

- M.Pharm in Pharmaceutics
- M.Pharm in Pharmacology
- M.Pharm in Pharmaceutical Chemistry
- M.Pharm in Quality assurance
- M.Pharm in Regulatory Affairs
- M.Pharm in Pharmacognosy
- M.Pharm in Pharmaceutical Biotechnology

Major  
Recruiters



**Latest  
news**



[www.gnipst.ac.in](http://www.gnipst.ac.in)



[www.facebook.com](http://www.facebook.com)



[www.instagram.com](http://www.instagram.com)



[www.linkedin.com](http://www.linkedin.com)



[www.youtube.com](http://www.youtube.com)



[api.whatsapp.com](http://api.whatsapp.com)